stars 1 stars 2 stars 3

Sapiens Steering Brain Stimulation is an emerging medical device company with a mission to bring the innovative concept of Steering Deep Brain Stimulation (DBS) to more patients who can benefit from this advanced treatment of degenerative or functional brain disorders, such as Parkinson's disease, dystonia and other currently emerging indications. Sapiens SBS ambition is to improve the therapeutic efficacy of DBS, to shorten and simplify the clinical procedure, and to improve patient comfort. Sapiens SBS high-resolution, MRI-conditionally safe SureStim-1® implant system enables the reduction of stimulation-induced side-effects by precisely shaping the stimulation field to the intended target area. The SureSuite® products, SurePlan®, SurePlace® and SureTune®, provide an integrated, image-based solution for planning and programming an optimal DBS treatment. With offices in Eindhoven, the Netherlands and Munich, Germany, Sapiens SBS was founded in 2011. The company is a spin-out of Royal Philips, and is backed by Wellington Partners, Edmond de Rothschild Investment Partners, Life Sciences Partners (LSP), the Wellcome Trust, INKEF Capital and Gilde Healthcare Partners. Additional support is provided by the Michael J Fox Foundation and the European Union Framework Program VII. Sapiens Steering Brain Stimulation lead, implant and image-guided programming are all based on patented technologies.

Sapiens Questions

The Sapiens annual revenue was $5 million in 2026.

Sapiens is based in Munich, Bavaria.

The NAICS codes for Sapiens are [621, 62, 62111, 621111, 6211].

The SIC codes for Sapiens are [80, 801].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users